August 2, 2021
Daiichi Sankyo’s April-June sales soared 11.4% over a year ago on the back of strong performances from global products Lixiana (edoxaban) and Enhertu (trastuzumab deruxtecan), with the iron deficiency treatment Injectafer (ferric carboxymaltose) also lending support. In the first quarter...read more